Premium
Rosiglitazone protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase‐9 expression
Author(s) -
Yao Xinming,
Ye Shandong,
Chen Yan,
Zai Zhiming,
Li Xiucai,
Wang Yingxin,
Chen Ke
Publication year - 2009
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2008.00990.x
Subject(s) - matrix metalloproteinase , matrix metalloproteinase 9 , rosiglitazone , renal injury , kidney , metalloproteinase , medicine , matrix metalloproteinase inhibitor , diabetes mellitus , endocrinology
In this study, the effects of rosiglitazone on renal matrix metalloproteinase‐9 (MMP‐9) expression and its possible renoprotective mechanisms were investigated in streptozotocin‐induced diabetic rats. We examined the urinary excretion rates of albumin (ALB), retinal‐binding protein (RBP) and MMP‐9 in control healthy rats (group C, n = 8), untreated diabetic rats (group D, n = 8) and diabetic rats treated with rosiglitazone (5mg/kg/day) (group R, n = 8) at eighth week. The renal tissue of diabetic rats was obtained for observing renal pathological changes by electron microscope and examining the expression of renal MMP‐9 mRNA by RT‐PCR. Our results showed that urinary excretion rates of MMP‐9. ALB and RBP were significantly increased concurrently with the expression of renal MMP‐9mRNA in group D compared with those of group C. Rosiglitazone significantly reduced urinary excretion rates of ALB, RBP and MMP‐9 as well as the expression of renal MMP‐9 mRNA. In addition, urinary excretion rate of MMP‐9 showed positive relationship with urinary excretion rates of ALB and RBP. In conclusion, rosiglitazone definitely protects diabetic rats against renal injury, which may be partly associated with decreasing expression of renal MMP‐9 mRNA and urinary MMP‐9 production.